PK and pharmacodynamic (PD) analyses from Cohorts 1 and 2 are ongoing, with results so far indicating that TTX-MC138's PK/PD profile aligns with preclinical and Phase 0 trial outcomes. Notably ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback